International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-5 doi: 10.5281/zenodo.10014914
Original Article
Foetomaternal Outcome In Heart Disaese During Pregnancy
 ,
 ,
 ,
Published
Oct. 17, 2023
Abstract

The incidence of cardiac disease in pregnancy is around 1%. Pregnancy complicated with cardiac disease is associated with increased risk of maternal morbidity & mortality. This study was conducted at Department of Obstetrics & Gynaecology, Government Medical College, Kottayam from September 2020 for one year. It was a prospective observational study done in 97 women who satisfied the inclusion criteria. Patients were classified as per modified WHO (World Health Organisation) pregnancy risk scoring.84.5% belonged to the age group of 20-34 years. Valvular heart disease(VHD) constituted 52.6% and congenital heart disease(CHD) 41.2%. Among VHD, mitral stenosis was most common, 23.5%.WHO class I,II,III&IV constituted 37.1%, 37.1%, 15.5% &10.3% respectively. Among 97 patients, 10 (10.3%) had to undergo MTP,31 (31.9%) underwent LSCS &56 (57.7%) underwent normal labour. The incidence of preterm labour was 5.7%, hypertension 11.5% and IUGR 8% which were more in WHO class IV. Congestive cardiac failure was the common complication which was observed in 4.1% of cases again observed in WHO risk IV cases.18 babies had birth weight less than 2500 g(20.7%). Low APGAR score<7 was observed in 5.7% of newborn and 5.7% of required NICU admission which was found to have significant association to modified WHO risk classification.1 case of stillbirth was observed (1.1%). There was no neonatal death. The incidence of congenital heart disease in neonate among patients with CHD was 5%.There was one case of maternal death.

Recommended Articles
Loading Image...
Volume-4, Issue-5
Citations
1550 Views
489 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved